Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Obinutuzumab in Newly Diagnosed Follicular Lymphoma
NCT06553352Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in follicular lymphoma (FL), sponsored by First Affiliated Hospital of Xiamen University. Started Mar 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06553352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553352.